2C-B-FLY

Last updated
2C-B-FLY
2C-B-FLY structure.svg
2C-B-FLY 3D BS.png
Clinical data
Routes of
administration
Oral
Drug class Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • 2-(4-Bromo-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C12H14BrNO2
Molar mass 284.153 g·mol−1
3D model (JSmol)
Melting point 310 °C (590 °F)
  • NCCc1c2CCOc2c(Br)c3CCOc13
  • InChI=1S/C12H14BrNO2/c13-10-9-3-6-15-11(9)7(1-4-14)8-2-5-16-12(8)10/h1-6,14H2 Yes check.svgY
  • Key:YZDFADGMVOSVIX-UHFFFAOYSA-N Yes check.svgY

2C-B-FLY is a psychedelic phenethylamine and designer drug of the 2C family. It was first synthesized in 1996 by Aaron Monte, Professor of Chemistry at UW-La Crosse. [1] [2]

Contents

This molecule was researched by Alexander Shulgin, and it was Ann Shulgin's favorite research chemical. [3]

Chemistry

2C-B-Fly in powder form 2C-B-FLY.jpg
2C-B-Fly in powder form

2C-B-FLY is 8-bromo-2,3,6,7-benzo-dihydro-difuran-ethylamine. The full name of the chemical is 2-(8-bromo-2,3,6,7-tetrahydrofuro[2,3-f] [1]benzofuran-4-yl)ethanamine. It has been subject of little formal study, but its appearance as a designer drug has led the DEA to release analytical results for 2C-B-FLY and several related compounds.

Analogs and derivatives

In theory, dihydro-difuran analogs of any of the 2Cx / DOx family of drugs could be made, and would be expected to show similar activity to the parent compounds, 2-CB, DOB, DOM, etc. In the same way that 2C-B-FLY is the dihydro-difuran analog of 2C-B, the 8-iodo equivalent, "2C-I-FLY," would be the dihydro-difuran analogue of 2C-I, and the 8-methyl equivalent, "2C-D-FLY," would be the dihydro-difuran analogue of 2C-D.

Other related compounds can also be imagined and produced in which the alpha carbon of the ethylamine sidechain is methylated, giving the amphetamine derivative DOB-FLY, with this compound being the dihydro-difuran analogue of DOB, which can be viewed as the fully unsaturated derivative of Bromo-DragonFLY.

When only one methoxy group of a 2Cx drug is cyclized into a dihydro-furan ring, the resulting compound is known as a "hemifly", (and these could be termed 2- or 5- "hemis," depending on where the single dihydro-furan ring is placed). And when an unsaturated furan ring is inserted, the compound is known as a "hemi-dragonfly". The larger, fully saturated, hexahydro-benzo-dipyran ring derivative has been referred to as "2C-B-MOTH." The 8-bromo group can also be replaced by other groups to produce compounds such as TFMFly.

A large number of symmetrical and asymmetrical derivatives can be produced by using different combinations of ring systems. Because the 2- and 5- positions (using the common phenylethylamine numbering scheme), the 2- and 5-positions of the benzene ring, if named as benzo-difurans are not equivalent.[ clarification needed ] Asymmetrical combinations have two possible positional isomers, with different pharmacological activities, at the various 5-HT2 subtypes. These compounds were casually referred to as the "2C-B-GNAT," and "2C-B-FLEA" compounds, which contain 5 or 6 membered rings at the 2- vs. 5-positions, respectively. Isomeric "Ψ"-derivatives with the oxygens positioned at the 2,6- positions, and mescaline analogues with the oxygens at 3,5- have also been made, but both are less potent than the corresponding 2,5- isomers. [8] [9] The symmetrical aromatic benzodifuran derivatives tend to have the highest binding affinity at 5-HT2A, but the saturated benzodifuran derivatives have higher efficacy, while the saturated benzodipyran derivatives are more selective for 5-HT2C. A large number of possible combinations have been synthesised and tested for activity, but these represent only a fraction of the many variations that could be produced. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20]

2C-BFLY and some selected analogues (SAR) Bfly structures for wiki2.png
2C-BFLY and some selected analogues (SAR)

Dosage

Alexander Shulgin lists a dosage of 2C-B-FLY from 10 to 20 mg orally.[ citation needed ]

Interactions

Toxicity

The toxicity of 2C-B-FLY in humans is unknown. Two deaths occurred in October 2009, in Denmark and the United States, after ingestion of a substance that was sold as 2C-B-FLY in a small-time RC shop, but in fact consisted of Bromo-DragonFLY contaminated with a small amount of unidentified impurities. [21]

Pharmacology

2C-B-FLY activities
Target Affinity (Ki, nM)
5-HT1A 147–350
5-HT1B 185
5-HT1D 1.4
5-HT1E 110
5-HT1F ND
5-HT2A 11–11.6 (Ki)
0.029–53.7 (EC50 Tooltip half-maximal effective concentration)
80–104% (Emax Tooltip maximal efficacy)
5-HT2B 0.9 (Ki)
0.123–40 (EC50)
56–108% (Emax)
5-HT2C 10.6–12 (Ki)
0.0615–0.149 (EC50)
100–108% (Emax)
5-HT3 >10,000
5-HT4 ND
5-HT5A >10,000
5-HT6 150
5-HT7 606
α1A 11,000
α1B >10,000
α1D ND
α2A 145–780
α2B 624
α2C 233
β1 >10,000
β2 >10,000
β3 ND
D1 1,400–4,963
D2 1,900–6,835
D3 6,800
D4 >10,000
D5 >10,000
H1 3,400–5,753
H2H4 >10,000
M1 643
M2 2,029
M3 339
M4 520
M5 873
I1 >10,000
σ1 >10,000
σ2 >10,000
TAAR1 Tooltip Trace amine-associated receptor 1710 (Ki) (mouse)
30 (Ki) (rat)
1,800 (EC50) (mouse)
270 (EC50) (rat)
>30,000 (EC50) (human)
49% (Emax) (mouse)
48% (Emax) (rat)
SERT Tooltip Serotonin transporter10,000 (Ki)
73,000 (IC50 Tooltip half-maximal inhibitory concentration)
(EC50)
NET Tooltip Norepinephrine transporter17,000 (Ki)
97,000 (IC50)
(EC50)
DAT Tooltip Dopamine transporter>26,000 (Ki)
187,000 (IC50)
(EC50)
MAO-A Tooltip Monoamine oxidase A19,000 (IC50)
MAO-B Tooltip Monoamine oxidase BND (IC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [22] [23] [24] [25] [26] [27] [28] [29]

2C-B-FLY is a potent agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, serotonin 5-HT2B, and serotonin 5-HT2C receptors. [24] [25] Unusually among 2C drugs, 2C-B-FLY also shows high affinity for the serotonin 5-HT1D receptor. [24] It also has relatively weak affinity for the serotonin 5-HT1A, 5-HT1B, and 5-HT1E receptors. [24] [25]

Legality

Canada

As of October 31, 2016; 2C-B-FLY is a controlled substance (Schedule III) in Canada. [30]

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market". [31]

United States

2C-B-FLY is unscheduled and uncontrolled in the United States. However, it may fall under the scope of the Federal Analog Act if it is intended for human consumption given its similarity to 2C-B.

References

  1. "Profile for Aaron Monte". UW-La Crosse. 2013-04-10.
  2. "Erowid 2C-B-Fly Vaults : 2C-B-FLY". erowid.org. Retrieved 2022-11-24.
  3. Ali, Nuit (28 February 2023). "2C-B-FLY, Ann Shulgin's Favourite Molecule". chemical-collective.com.
  4. "Explore N-(2C-B)-Fentanyl | PiHKAL · info". isomerdesign.com.
  5. "Explore N-(2C-FLY)-Fentanyl | PiHKAL · info". isomerdesign.com.
  6. Glennon, Richard A.; Bondarev, Mikhail L.; Khorana, Nantaka; Young, Richard; May, Jesse A.; Hellberg, Mark R.; McLaughlin, Marsha A.; Sharif, Najam A. (November 2004). "β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 47 (24): 6034–6041. doi:10.1021/jm040082s. ISSN   0022-2623. PMID   15537358.
  7. Beta-hydroxyphenylalkylamines and their use for treating glaucoma
  8. Monte AP; et al. (September 1997). "Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives". Journal of Medicinal Chemistry. 40 (19): 2997–3008. CiteSeerX   10.1.1.690.9370 . doi:10.1021/jm970219x. PMID   9301661.
  9. Chambers JJ, Kurrasch-Orbaugh DM, Nichols DE (August 2002). "Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity". Bioorganic & Medicinal Chemistry Letters. 12 (15): 1997–9. CiteSeerX   10.1.1.688.9483 . doi:10.1016/S0960-894X(02)00306-2. PMID   12113827.
  10. Nichols DE; et al. (January 1991). "2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines". Journal of Medicinal Chemistry. 34 (1): 276–81. doi:10.1021/jm00105a043. PMID   1992127.
  11. Monte AP; et al. (July 1996). "Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups". Journal of Medicinal Chemistry. 39 (15): 2953–61. doi:10.1021/jm960199j. PMID   8709129.
  12. Parker, MA (1998). Studies of perceptiotropic phenethylamines: Determinants of affinity for the 5-HT2A receptor (PhD. Thesis). Purdue University. Archived from the original on 2012-04-25. Retrieved 2011-12-16.
  13. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (March 2001). "Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists". Journal of Medicinal Chemistry. 44 (6): 1003–10. CiteSeerX   10.1.1.691.362 . doi:10.1021/jm000491y. PMID   11300881.
  14. Whiteside MS; et al. (October 2002). "Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes". Bioorganic & Medicinal Chemistry. 10 (10): 3301–6. CiteSeerX   10.1.1.1010.6813 . doi:10.1016/S0968-0896(02)00209-2. PMID   12150876.
  15. Chambers JJ; et al. (July 2003). "Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands". Journal of Medicinal Chemistry. 46 (16): 3526–35. CiteSeerX   10.1.1.688.3544 . doi:10.1021/jm030064v. PMID   12877591.
  16. Schultz DM; et al. (June 2008). ""Hybrid" Benzofuran–Benzopyran Congeners as Rigid Analogues of Hallucinogenic Phenethylamines". Bioorganic & Medicinal Chemistry. 16 (11): 6242–51. doi:10.1016/j.bmc.2008.04.030. PMC   2601679 . PMID   18467103.
  17. Evans, Paul (2000). Design and Synthesis of Novel 5-HT2A/2C Receptor Agonists (PDF) (PhD.). University of Wisconsin-La Cross. Archived from the original (PDF) on 2011-07-16. Retrieved 2010-05-27.
  18. Heim, Ralf (2004). Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts (PhD.). Der Freien Universität Berlin.
  19. Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University. ProQuest   304838368.
  20. Silva, Maria (2009). Theoretical study of the interaction of agonists with the 5-HT2A receptor (PhD.). Universität Regensburg.
  21. "Erowid 2C-B-Fly Vault: Death Reports 2009". www.erowid.org. Retrieved 18 December 2022.
  22. "Kᵢ Database". PDSP. 16 March 2025. Retrieved 16 March 2025.
  23. Liu T. "BDBM50052339 2-(8-Bromo-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b']difuran-4-yl)-ethylamine::CHEMBL101189". BindingDB. Retrieved 3 March 2025.
  24. 1 2 3 4 Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi: 10.1371/journal.pone.0009019 . PMC   2814854 . PMID   20126400.
  25. 1 2 3 Rickli A, Kopf S, Hoener MC, Liechti ME (July 2015). "Pharmacological profile of novel psychoactive benzofurans". Br J Pharmacol. 172 (13): 3412–3425. doi:10.1111/bph.13128. PMC   4500375 . PMID   25765500.
  26. Pottie E, Cannaert A, Stove CP (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol. 94 (10): 3449–3460. Bibcode:2020ArTox..94.3449P. doi:10.1007/s00204-020-02836-w. hdl: 1854/LU-8687071 . PMID   32627074.
  27. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC   10724237 . PMID   38102107.
  28. Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Test Anal. 11 (2): 318–324. doi:10.1002/dta.2494. PMID   30188017.
  29. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID   26791601.
  30. Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)
  31. https://finlex.fi/fi/laki/ajantasa/2014/20141130